Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00076622
Status:
COMPLETED
Last Update Posted:
2018-01-31
First Post:
2004-01-28
Brief Title:
Medication Treatment for Depression in Nursing Home Residents
Sponsor:
University of Pennsylvania
Organization:
University of Pennsylvania
Study Overview
Official Title:
Drug Treatment of Depression in the Nursing Home Aged
Status:
COMPLETED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will examine therapeutic and adverse effects of continuing versus discontinuing antidepressant medication in nursing home residents who have had no more than a single episode of depression and who no longer have depressive symptoms
Detailed Description:
There are approximately 16 million nursing home residents in the United States More than one third of these residents are taking antidepressant medications ADs Although ADs are effective evidence suggests that they can lead to significant adverse events including an increased risk of falls and bone fractures Many depressed nursing home residents suffer from an initial episode of late-life depression and do not meet guideline-based recommendations for maintenance treatment This study will examine the benefits and risks of long-term AD treatment in depressed nursing home residents whose single episode of depression has been in continuous remission for at least six months
Participants will be randomly assigned to either continue or discontinue AD treatment Participants will be monitored over a period of one year for recurrence of depression and related symptoms as well as for the occurrence of falls fractures and other adverse events Medical chart review self-reported mood symptoms and depression scales will be used to assess participants
Participants will be randomly assigned to either continue or discontinue AD treatment Participants will be monitored over a period of one year for recurrence of depression and related symptoms as well as for the occurrence of falls fractures and other adverse events Medical chart review self-reported mood symptoms and depression scales will be used to assess participants
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R37MH051247 | NIH | None | None |
| DSIR AT-GP | US NIH GrantContract | None | httpsreporternihgovquickSearchR37MH051247 |